Replimune Group Inc. Financials
REPL
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | MAR 2026 | MAR 2025 | MAR 2024 | MAR 2023 | MAR 2022 |
|---|---|---|---|---|---|
| General & Administrative | $99 | $72 | $60 | $51 | $39 |
| Research & Development | $221 | $189 | $175 | $127 | $80 |
| Total Operating Expenses | $320 | $262 | $235 | $177 | $118 |
| Operating Income | -$320 | -$262 | -$235 | -$177 | -$118 |
| Non-Operating | |||||
| Net Interest Expense | $7 | $15 | $19 | $8 | $0 |
| Other Non-Operating Income (Expense) | -$1 | -$1 | $1 | -$5 | -$0 |
| EBT (Earnings Before Tax) | -$314 | -$247 | -$215 | -$174 | -$118 |
| Income Tax Expense | -$1 | $0 | $0 | $0 | $0 |
| Earnings from Continuing Ops | -$314 | -$247 | -$215 | -$174 | -$118 |
| Net Income | |||||
| Net Income | -$314 | -$247 | -$216 | -$174 | -$118 |
| EPS (Basic) | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 |
| EPS (Diluted) | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 |
| Weighted Avg Shares (Basic) | 92.8M | 80.6M | 66.6M | 58.2M | 52.2M |
| Weighted Avg Shares (Diluted) | 92.8M | 80.6M | 66.6M | 58.2M | 52.2M |
| Shares Outstanding | 92.8M | 80.6M | 66.6M | 58.2M | 52.2M |
Replimune Group (REPL) financials: revenue, profit and margins
Replimune Group (REPL) generated about n/a in revenue and -$271 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Replimune Group profitable?+
Replimune Group reported about -$271 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 23 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.
Fiscal year ends Mar.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL
Held by ETFs
REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:
Spot a number that looks wrong? Check it in REPL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing REPL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.